Rakuten Medical, a global biotechnology company developing and commercializing its proprietary Alluminox platform-based photoimmunotherapy, announced the closing of a $100 million Series F financing round. This includes $70 million in new capital and the conversion of $30 million in convertible promissory notes with accrued interest.